Search research articles
Contact Us
Filters
Showing results (41-50 of 97) with videos related to
Page
of 10
Sort By:
Blood Cancer Journal
|
April 28, 2026
Immune effector cell-associated enterocolitis post-BCMA directed CAR T-cell therapy: insights from a multicenter case series
Sandra Susanibar-Adaniya, Benjamin A Derman, Adam D Cohen, et al.
Transplantation and Cellular Therapy
|
March 13, 2026
Characterization of Hypogammaglobulinemia, Infection Incidence, and Mortality in Patients Receiving B-cell Maturation Antigen Chimeric Antigen Receptor (CAR) T-cell Therapy
Katherine J Liu, Lingxiao Zhang, Baijun Zhou, et al.
The Lancet. Haematology
|
April 27, 2024
Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial
Elizabeth O'Donnell, Clifton Mo, Andrew J Yee, et al.
Ejhaem
|
August 21, 2023
Selinexor: Targeting a novel pathway in multiple myeloma
Clifton C Mo, Andrew J Yee, Shonali Midha, et al.
Blood Advances
|
March 14, 2025
Early daratumumab therapy improves renal outcomes in newly diagnosed myeloma patients admitted with kidney injury
E Bridget Kim, Jack E Malespini, Matthew Lei, et al.
Cancer
|
September 11, 2019
Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma
Jeremy S Abramson, Kelly E Irwin, Matthew J Frigault, et al.
The Spine Journal : Official Journal of the North American Spine Society
|
October 16, 2025
Efficacy of bone-modifying agents in preventing vertebral complications of multiple myeloma: a systematic review and meta-analysis
Zsombor T Gal, Ethan A Wetzel, Brian V Nahed, et al.
Leukemia
|
December 19, 2025
Prognostic value of serological and PET/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-T
Joshua N Gustine, John A Scaringi, Fabian Bauer, et al.
Expert Review of Hematology
|
July 26, 2024
Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide
Yuxin Liu, Clifton C Mo, Monique A Hartley-Brown, et al.
Leukemia & Lymphoma
|
July 21, 2025
BCMA-targeting BiTE molecule AMG 420 in relapsed or refractory multiple myeloma: a phase 1b open-label expansion study
Cesar Rodriguez, Tulio Rodriguez, Alain Kentos, et al.
Page
of 10
Search research articles
Search
Showing results (41-50 of 97) with videos related to
Sort By:
Page
of 10
Blood Cancer Journal
|
April 28, 2026
Immune effector cell-associated enterocolitis post-BCMA directed CAR T-cell therapy: insights from a multicenter case series
Sandra Susanibar-Adaniya, Benjamin A Derman, Adam D Cohen, et al.
Transplantation and Cellular Therapy
|
March 13, 2026
Characterization of Hypogammaglobulinemia, Infection Incidence, and Mortality in Patients Receiving B-cell Maturation Antigen Chimeric Antigen Receptor (CAR) T-cell Therapy
Katherine J Liu, Lingxiao Zhang, Baijun Zhou, et al.
The Lancet. Haematology
|
April 27, 2024
Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial
Elizabeth O'Donnell, Clifton Mo, Andrew J Yee, et al.
Ejhaem
|
August 21, 2023
Selinexor: Targeting a novel pathway in multiple myeloma
Clifton C Mo, Andrew J Yee, Shonali Midha, et al.
Blood Advances
|
March 14, 2025
Early daratumumab therapy improves renal outcomes in newly diagnosed myeloma patients admitted with kidney injury
E Bridget Kim, Jack E Malespini, Matthew Lei, et al.
Cancer
|
September 11, 2019
Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma
Jeremy S Abramson, Kelly E Irwin, Matthew J Frigault, et al.
The Spine Journal : Official Journal of the North American Spine Society
|
October 16, 2025
Efficacy of bone-modifying agents in preventing vertebral complications of multiple myeloma: a systematic review and meta-analysis
Zsombor T Gal, Ethan A Wetzel, Brian V Nahed, et al.
Leukemia
|
December 19, 2025
Prognostic value of serological and PET/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-T
Joshua N Gustine, John A Scaringi, Fabian Bauer, et al.
Expert Review of Hematology
|
July 26, 2024
Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide
Yuxin Liu, Clifton C Mo, Monique A Hartley-Brown, et al.
Leukemia & Lymphoma
|
July 21, 2025
BCMA-targeting BiTE molecule AMG 420 in relapsed or refractory multiple myeloma: a phase 1b open-label expansion study
Cesar Rodriguez, Tulio Rodriguez, Alain Kentos, et al.
Page
of 10